Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Fees Could Be Based On Product Complexity

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA seeks comments at Sept. 17 public hearing on issues surrounding development of an ANDA user fee program, including whether applications for more complex products should carry a higher fee and whether fees should be used to support postmarketing safety oversight.
Advertisement

Related Content

Generic User Fee Negotiations: Should Different Kinds Of ANDAs Pay More?
Generic User Fee Negotiations: Should Different Kinds Of ANDAs Pay More?
ANDA User Fee Negotiations: A Big-Firm Coalition Tackles The Big Backlog
ANDA User Fee Negotiations: A Big-Firm Coalition Tackles The Big Backlog
FDA Expects Sharp Drop In Drug Applications This Year
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
Generic User Fees Face Opposition From Key House Appropriator DeLauro
Generic User Fees Face Opposition From Key House Appropriator DeLauro
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office

Topics

Advertisement
UsernamePublicRestriction

Register

PS071138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel